COVID-19 Single shot

Single shot COVID-19 vaccine promising efficacy from Johnson & Johnson

COVID-19

A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts.
The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan. 13 in the New England Journal of Medicine.

COVID-19 Single shot

The Johnson & Johnson vaccine also would be hardier than either of the already approved vaccines because it relies on DNA technology rather than messenger RNA to prompt an immune system response.

The new vaccine is made up of a deactivated cold virus into which scientists cut-and-paste a genetic version of the “spike” protein used by the coronavirus to infect cells. The immune system recognizes the incomplete and harmless coronavirus protein as an invader and mounts a response, learning how to ward off any future infections from the actual coronavirus.

References:

www.drugs.com

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
🏷️ WANT A COUPON
Give us a review on Google or Facebook
Google Review

Facebook Review
and Subscribe now to get free discount coupon code. Don't miss out

    SUBSCRIBE